Literatur
McAllister DA. Incidence of Hospitalization for Heart Failure and Case-Fatality Among 3,25 Million People With and Without Diabetes Mellitus. Circulation. 2018; 138(24),2774-86
Davies MJ et al. Management of hyperglycaemia in type 2 diabetes - A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61,2461-98
Cosentino F et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Associ. European Heart Journal 2020;41(2):255-323
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359,1577-89
Ferrannini E. The target of metformin in type 2 diabetes. N Engl J Med 2014:371,1547-8
Aroda VR et al. Diabetes Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab 2016;101,1754-61
UK Prospective Diabetes Study (UKPDS) Group. UKPDS Study. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352,854-65
Griffin SJ et al. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trails among people with type 2 diabetes. Diabetologia 2017;60,1620-9
Mallik R et al. Metformin in cancer. Diabetes Res Clin Pract 2018;143,409-19
Tseng CH. Metformin reduces risk of benign goiter in patients with type 2 diabetes mellitus. Eur J Endocrinol. 2019;180,365-72
Monami M et al. Short and medium-term efficacy of sodium glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of. Diabetes Obes Metab. 2018;20,5,1213-22
Wiviott SD et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380 347-57
Zelniker TA et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019;393,10166,31-9
Zinman B et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015;373,2117-28
McMurray JJV et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381,1995-2008
Perkovic V et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380,24, 2295-306
Heerspink HJL. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383,1436-46
Gerstein HC. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394,121-30
Husain M. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381,841-51
Rosenstock J et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes. JAMA. 2019;322,12,1155-66
Ling J et al. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials. Acta Diabetologca 2019;56,249-72
Rosenstock J. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk. The CARMELINA randomized clinical trial. JAMA 2019;321,69-79
Buse JB et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2020;63,221-8
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Die Autorin erklärt: Forschungsförderung: keine; Honorare, Kostenerstattung: Boehringer Ingelheim, Forum für medizinische Fortbildung, Ipsen, Lilly, Medifora, Novo Nordisk, Sanofi; Beratertätigkeit: Boehringer Ingelheim; Patent/Geschäftsanteile/Aktien: keine
Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.
Rights and permissions
About this article
Cite this article
Negrean, M. Orale Antidiabetika bei Typ-2-Diabetes. Info Diabetol 14, 28–39 (2020). https://doi.org/10.1007/s15034-020-2209-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15034-020-2209-8